

## SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the Global Offering and assuming that the Over-allotment Option is not exercised, the following persons will have interests and/or short positions (as applicable) in the Shares or underlying shares of our Company, which would be required to be disclosed to us and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO or will, directly or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at the general meetings of our Company or any other members of our Group:

Name of Shareholder	Nature of interest	Shares held as of the date of this prospectus immediately prior to the completion of the Global Offering <sup>(1)</sup>		Shares held immediately following the completion of the Global Offering	
		Number	Approximate Percentage	Number	Approximate Percentage
MP Scientific <sup>(2)</sup>	Beneficial owner	310,871,340 (L)	54.64%	310,871,340 (L)	53.35%
MicroPort <sup>(2)</sup>	Interest of controlled corporation	310,871,340 (L)	54.64%	310,871,340 (L)	53.35%
WE'TRON Capital <sup>(3)</sup>	Beneficial owner	60,526,500 (L)	10.64%	60,526,500 (L)	10.39%
Maxwell Maxcare Science Foundation Limited ("Maxwell Maxcare") <sup>(3)(4)</sup>	Interest of controlled corporation	63,915,000 (L)	11.24%	63,915,000 (L)	10.97%
Biolink Limited	Beneficial owner	41,996,875 (L)	7.38%	41,996,875 (L)	7.21%
Biolink Fund Limited Partnership <sup>(5)</sup>	Interest of controlled corporation	41,996,875 (L)	7.38%	41,996,875 (L)	7.21%
Biolink Biomedical Ltd. ("Biolink Biomedical") <sup>(5)(6)</sup>	Interest of controlled corporation	58,795,625 (L)	10.33%	58,795,625 (L)	10.09%
Lion Fish Limited <sup>(5)(6)</sup>	Interest of controlled corporation	58,795,625 (L)	10.33%	58,795,625 (L)	10.09%
Thriving Hope Limited <sup>(5)(6)</sup>	Interest of controlled corporation	58,795,625 (L)	10.33%	58,795,625 (L)	10.09%
Blossom Vision Limited <sup>(5)(6)</sup>	Interest of controlled corporation	58,795,625 (L)	10.33%	58,795,625 (L)	10.09%
Suntera Corporate Trustees (Hong Kong) Limited <sup>(5)(6)</sup>	Trustee of discretionary trust	58,795,625 (L)	10.33%	58,795,625 (L)	10.09%
Hu Yibin <sup>(5)(6)(7)</sup>	Settlor of discretionary trust and interest of controlled corporation	61,558,955 (L)	10.82%	61,558,955 (L)	10.57%

Notes:

(1) The letter "L" denotes a long position in our Shares.

(2) MP Scientific is directly wholly owned by MicroPort. By virtue of the SFO, MicroPort is deemed to be interested in the Shares in which MP Scientific is interested.

---

## SUBSTANTIAL SHAREHOLDERS

---

- (3) WE'TRON Capital is directly owned as to 99.99% by Maxwell Maxcare. By virtue of the SFO, Maxwell Maxcare is deemed to be interested in the Shares held by WE'TRON Capital.
- (4) Maxwell Maxcare is also the sole shareholder of Miracle Medical Limited. Miracle Medical Limited held 3,388,500 Shares, representing approximately 0.60% and 0.58% of our Shares in issue immediately prior to and following the completion of the Global Offering (without taking into account any Shares which may be issued pursuant to the exercise of the Over-allotment Option), respectively. By virtue of the SFO, Maxwell Maxcare is deemed to be interested in the Shares held by Miracle Medical Limited.
- (5) Each of Biolink Fund Limited Partnership (as the sole shareholder of Biolink Limited), Biolink Biomedical (as the general partner of Biolink Fund Limited Partnership), Lion Fish Limited (as the sole shareholder of Biolink Biomedical), Thriving Hope Limited (as the sole shareholder of Lion Fish Limited), Blossom Vision Limited (as the sole shareholder of Thriving Hope Limited), Suntera Corporate Trustees (Hong Kong) Limited (as the trustee of a discretionary trust (the "Trust") and the sole shareholder of Blossom Vision Limited) and Hu Yibin (the settlor of the Trust) is deemed to be interested in the Shares held by Biolink Limited by virtue of the SFO.
- (6) Biolink Biomedical is also the general partner of Biolink NT Fund Limited Partnership, which is the sole shareholder of Biolink NT. As such, each of Biolink Biomedical, Lion Fish Limited, Thriving Hope Limited, Blossom Vision Limited, Suntera Corporate Trustees (Hong Kong) Limited and Hu Yibin is deemed to be interested in the Shares held by Biolink NT by virtue of the SFO. Biolink NT held 16,798,500 Shares, representing approximately 2.95% and 2.88% of our Shares in issue immediately prior to and following the completion of the Global Offering (without taking into account any Shares which may be issued pursuant to the exercise of the Over-allotment Option), respectively.
- (7) Hu Yibin holds 100% voting power in Biolink Healthcare. Biolink Healthcare held 2,763,330 Shares, representing approximately 0.49% and 0.48% of our Shares in issue immediately prior to and following the completion of the Global Offering (without taking into account any Shares which may be issued pursuant to the exercise of the Over-allotment Option), respectively. By virtue of the SFO, Hu Yibin is deemed to be interested in the Shares held by Biolink Healthcare.

If the Over-allotment Option is fully exercised, the interest of MP Scientific, MicroPort, WE'TRON Capital, Maxwell Maxcare, Biolink Limited, Biolink Fund Limited Partnership, Biolink Biomedical, Lion Fish Limited, Thriving Hope Limited, Blossom Vision Limited, Suntera Corporate Trustees (Hong Kong) Limited and Hu Yibin in our Shares will be approximately 53.17%, 53.17%, 10.35%, 10.93%, 7.18%, 7.18%, 10.06%, 10.06%, 10.06%, 10.06%, 10.06% and 10.53%, respectively.

Save as disclosed above and the section headed "Statutory and General Information—C. Further Information about Our Directors and Substantial Shareholders—3. Disclosure of interests" in Appendix IV to this prospectus, our Directors are not aware of any person who will, immediately following completion of the Global Offering (assuming the Over-allotment Option is not exercised), have beneficial interests or short positions in any Shares or underlying Shares, which would be required to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly interested in 10% or more of the issued voting shares of any member of our Group. Our Directors are not aware of any arrangement which may at a subsequent date result in a change of control of our Company.